No Recall Yet for Type 2 Diabetes Drug, Actos
By Independent Staff Writer
The FDA has joined forces with France and Germany regarding a warning about the Type 2 diabetes drug, pioglitazone, however no recall is expected at this time. Pioglitazone, also known as Actos, is manufactured by Takeda Pharmaceuticals, a Japanese drug company. The drug currently accounts for some 27% of Takeda’s annual revenues. 2008 saw this powerhouse diabetes medication become the tenth best-selling prescription medication in the United States. Over the past year, Takeda has accrued nearly $4.8 billion dollars in revenues through worldwide sales of Actos.
Clinical Studies of Pioglitazone
Pre-clinical studies—in which male rats were given body-weight equivalent doses of Actos—showed an increase in the incidence of bladder cancer while two subsequent clinical studies using human subjects also revealed an elevated risk of bladder cancer. Due to these findings, the FDA mandated that the potential risks be revealed on the label of the drug, ordering a safety review in September, 2010. Takeda additionally agreed to carry out a ten-year observational study in those diabetic patients currently taking Actos, to be conducted on patients from Kaiser Permanente Northern California Health Plan.
Results of Safety Review
Although the results of the FDA-ordered safety review of pioglitazone were less than positively conclusive, the French Agency for the Safety of Health Products nonetheless pulled Actos from the French market this June due to health concerns. France conducted their own safety study, using over 1.5 million diabetic patients who were currently being treated with the drug—a study which more definitively showed a positive correlation between bladder cancer and pioglitazone. This study also pointed to the fact that the risk increases in patients who take the drug for a longer time period than one year. Following on the heels of the French decision, the German Federal Institute for Drugs and Medical Devices advised doctors against prescribing Actos, based on the French study results. As of September, 2011, no other countries have pulled the drug due to safety concerns.
Specific Issues Related to Safety Reviews
The FDA believes the risk of bladder cancer rises following an increase in dosage or use of longer than a year, citing a 40% increased risk in those who fell in these categories. Because the elderly are already more susceptible to bladder cancer an alternative diabetic drug should be used in older patients. The FDA further asserted that doctors should use extreme caution and full assessments when prescribing Actos, avoiding using the drug on those with active bladder cancer or those with a history of this type of cancer. Expect continued updates on the safety of Actos as further studies are concluded.
DISCLAIMER: All cases are based on individual circumstances and the facts pertaining to each case, and the outcome for any particular case depends on a variety of factors. None of the information provided on this website should suggest or guarantee a particular result for any given case. None of the information provided on this website should be construed in any way as legal advice. Further, none of the information provided on this website should suggest or imply the formation of an attorney-client relationship in any capacity whatsoever.
|
|
|
|
|
|
|
|
|
|
Free Consultation
|
|
Receive an immediate response to your request.
|
|
|
|
|
|
|
Recent Articles and Publications
|
|
|
|
April 25, 2012
|
|
Recovering From Actos-Related Bladder Cancer: Part 1of 2: How Can I Prevent a Recurrence?
|
|
Actos, or pioglitazone, is a prescription medicine used in the treatment of Type-2 diabetes and works by sensitizing cells to the pancreas-produced hormone known as insulin. Insulin is used by the body to regulate the amount of sugar or glucose in the body therefore when cells are more sensitive to insulin, sugar in the blood naturally moves more easily into cells.
|
|
Full Story
|
|
|
|
|
April 23, 2012
|
|
Recovering From Actos-Related Bladder Cancer: Part 2 of 2: What All Actos Users Should Know:
|
|
Actos, a drug used in the treatment of Type 2 Diabetes has been shown to carry a risk of bladder cancer, particularly among those who are elderly or who have taken the drug in higher doses or for extended periods of time (longer than one year). Although the drug has not yet been recalled by the FDA, it has fallen under intense scrutiny and has been pulled from the French and German markets.
|
|
Full Story
|
|
|
|
|
March 03, 2012
|
|
Actos Discussions Part 2: Dangers of the Drug
|
|
Links to higher heart disease rates have been associated with the use of Actos, and, in fact, Actos may cause as many heart problems as GlaxoSmithKline’s drug, Avandia. The American Heart Association reported that studies showed patients taking either diabetes drug were at least four times as likely to experience heart attacks, heart failure or even death.
|
|
Full Story
|
|
|
|
No article available
|
|
|
|
|
|